Grafix® is a cryopreserved placental membrane that retains the extracellular matrix, growth factors, and endogenous cells of the native tissue.
• Flexible, conforming cover that naturally adheres to complex anatomies and may be used over exposed bone, tendon, joint capsule, muscle, and hardware
• Designed for application directly to acute and chronic wounds
• Immune neutral
• Alternative to autologous skin grafting that eliminates the pain, comorbidities and procedure time associated with obtaining autologous grafts
• No need for sutures or Steri-Strips®
• Available in multiple sizes to reduce wastage
Grafix® naturally conforms to complex anatomies and may be used over exposed bone, tendon, joint capsule, muscle and hardware. Grafix® may be used to repair acute and chronic wounds, encompassing both upper extremity and lower extremity, including but not limited to: diabetic foot ulcers, venous leg ulcers, pressure ulcers, dehisced surgical wounds, burns, acute surgical wounds, pyoderma gangrenosum and epidermolysis bullosa. The product is limited to the homologous use as a wound cover.
There are no known contraindications for Grafix®.
Intended for use in one patient, on a single occasion only.
Do not use if package integrity has been compromised. Once the user breaks the seal on the pouch, the tissue grafts must be transplanted or discarded.
The tissue may not be sterilized.
The tissue is intended for use by qualified health care specialists such as physicians, podiatrists, or other appropriate health care professionals.
The same medical/surgical conditions or complications that apply to any medical/surgical procedure may occur during or following application.
The health care professional is responsible for informing the patient of the risks associated with his/her treatment and the possibility of complications or adverse reactions.
Caution should be exercised for patients with known sensitivities for reagents used for processing, disinfection, and storage which may remain on the product.
Donor screening methods are limited; therefore, certain diseases may not be detected. The following complications of tissue transplantation may occur:
• Transmission of disease of unknown etiology;
• Transmission of known infectious agents including, but not limited to, viruses, bacteria, and fungi;
• Immune rejection of implanted Grafix®; or
• Loss of function and/or integrity of Grafix® due to resorption, fragmentation, and/or disintegration.
Please promptly report possible adverse event outcomes to Osiris Therapeutics, Inc. at 888-674-9551.
Grafix® has a minimum two year shelf life and should be stored frozen at -75°C to -85°C (-103°F to -121°F).
Native amnion or chorion tissue which contain extracellular matrix, growth factors, and endogenous neonatal cells
|Assigned HCPCS code||●|
|Shelf life greater than 2 years||●|
|Shelf life limited|
|Indicated for acute wounds||●|
|Indicated for chronic wounds||●|
|Indicated for diabetic ulcers||●|
|Indicated for pressure ulcers||●|
|Indicated for surgical wounds||●|
|Indicated for third-degree burns||●|
|Indicated for venous ulcers||●|
|Contact manufacturer for usage guidelines|
|Educational Material Available||●|
|Free Samples/Trials Available|
|Published Clinical Article Available||●|
Venous Leg Ulcers
Grafix® can be applied in an office, hospital outpatient setting, or in an operating room.
Reapply weekly at the discretion of the responsible physician for the duration of treatment.
Non-adherent dressing and outer dressings.
Grafix® cryopreserved placental membrane is supplied frozen in sheet form and packaged in a sterile cryobag contained within a heat-sealed pouch contained within a tertiary box. This packaging configuration allows for the introduction of Grafix® into the sterile field.
Neither Osiris Therapeutics, Inc. (Osiris), nor its affiliates expressly or by implication WARRANT any tissue selected, recovered, processed or distributed by itself, distributors, representatives, or agents. Please promptly report adverse outcomes to Osiris at 888-674-9551.
Donor eligibility is determined based on FDA screening and testing criteria, which includes testing for the following:
Human Immunodeficiency Virus Type 1 Antibody (HIV)
Human Immunodeficiency Virus Type 2 Antibody (HIV)
Hepatitis C Virus Antibody (HCV)
Hepatitis B Surface Antigen (HBV)
Hepatitis B Core Antibody (HBV)
Syphilis Rapid Plasma Reagin (RPR) or Treponemal Specific Assay
Human T-Cell Lymphotrophic Virus Type I Antibody (HTLV)
Human T-Cell Lymphotrophic Virus Type II Antibody (HTLV)
HIV/HCV/HBV Nucleic Acid Test (NAT)
West Nile Virus (WNV) Nucleic Acid Test (NAT) for tissue acquired from June 1 through October 31
Each lot must be sterility negative per USP<71>
Live cells present across 70% of the membrane sampled
Growth factors are present in Grafix PRIME®
Osiris Therapeutics, Inc. researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall health care costs.